ABL Diagnostics Announces CE-IVD of DeepChek® Whole Genome HIV-1 Genotyping v1.2

▤ Summary

ABL Diagnostics has announced CE-IVD registration for DeepChek Whole Genome HIV-1 Genotyping v1.2. The assay provides comprehensive HIV drug resistance testing using next-generation sequencing and improves sensitivity while preserving existing laboratory workflows. It covers nearly the entire HIV genome and supports resistance analysis across multiple antiretroviral drug classes, including newer therapies like lenacapavir. The company says the product integrates with major sequencing platforms, bioinformatics tools, and laboratory automation to support routine clinical diagnostics and research use.

▦ Linked Companies

ABL Diagnostics S.A.

$5M to $10M